- Revelation Biosciences Inc (NASDAQ:REVB) announced positive results in a preclinical model of acute kidney injury (AKI), a chronic kidney disease (CKD).
- Treatment with REVTx-300 significantly reduced renal cortical fibrosis in a dose-dependent manner in the medium and high-dose groups (21.7% reduction and 29.3%, respectively).
- The reduction was comparable to a known TGF-β inhibitor of fibrosis used as a positive control (38.1% reduction).
- Related: Revelation Biosciences Surges After Encouraging Data From Allergic Rhinitis Study.
- "These promising preclinical results offer hope of new prophylactic option for preventing the deleterious effects of AKI following multiple types of surgery," said Lakhmir Chawla, M.D. at the Jennifer Moreno Department of Veterans Affairs Medical Center, San Diego, CA, and a leading expert in AKI, "as well as potential new treatment options for active acute kidney injury and chronic kidney disease. I look forward to collaborating with Revelation as REVTx-300 moves through the development process."
- Revelation will continue evaluating the potential of REVTx-300 in additional preclinical models, including CKD, nonalcoholic steatohepatitis, and myocarditis, to identify optimal dosing conditions, to commence in Q4 2022.
- Revelation plans to initiate Phase 1 clinical studies in 1H of 2023.
- Price Action: REVB shares are up 68.20% at $0.42 on the last check Tuesday.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
